Strategic Asset Sales Sangamo recently filed for Chapter 11 bankruptcy and completed asset sales to Eli Lilly, transferring key platforms such as capsid delivery, ZFN, MINT and a prion program. This creates opportunities to pursue licensing, co development, or acquisition discussions around remaining assets or redirected programs with Lilly or other pharma buyers.

Partnership Opportunities With restructuring underway and a subset of staff retained to advance core programs, there is room for external partnerships or services to bridge funding gaps. Potential opportunities include licensing deals, CRO/CMO collaborations, and manufacturing partnerships that align with the assets still under consideration by bidders.

ASGCT Pipeline Focus Sangamo continues to participate in ASGCT events and showcase pipeline and technology advances, signaling open avenues for collaborations in neurology and gene regulation, including co development, research partnerships, or technology licensing with interested biopharma and academic groups.

Financial Health Signals The revenue range of 100-250 million and ongoing bankruptcy process indicate a distressed but valuable platform company. This presents opportunities for milestone driven partnerships, licensing of assets, or selective asset monetization to reduce risk for potential buyers.

Compliance and Security Sangamo emphasizes data privacy and cybersecurity readiness with a stack including OneTrust HIPAA, Azure Active Directory, Defender and a NIST framework, which may appeal to partners needing regulated data management, compliant cloud infrastructure, and secure clinical data handling in any post bankruptcy arrangements.